Saturday 17 October 2026
Export PTGX’s income statement to Excel — free account
Protagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024. In the quarter to June 2026, revenue grew 3,749.2%, EPS grew 549.1% and free cash flow grew 839.7%, each against the same quarter a year earlier.
128.75
7.80
−5.71%
Follow PTGX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | — | 2 | 7 |
| 7.80% | (20.18%) | (17.06%) | 10.98% | ||
| 7.03% | (18.42%) | (15.94%) | 10.34% | ||
ROIC |
17.14% | (208.75%) | (82.68%) | 61.84% | |
Return on Tangible Assets |
8.41% | (24.28%) | (19.69%) | 10.72% | |
Average Days of Receivables |
1.02 | 0.96 | 264.46 | 17.37 | |
Free Cash Flow per Share |
1.00 | 0.88 | (1.81) | 1.98 | |
Free Cash Flow |
63.71 | 56.08 | (117.89) | 130.58 | |
Capital Expenditures |
(1.76) | (1.59) | (1.26) | (0.61) | |
| Other line items | |||||
Cash ROIC |
5.22% | 4.74% | (9.80%) | 8.04% | |
Accounts Receivable Turnover |
39.54 | 0.31 | 2.76 | 3.16 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.02 | 0.01 | (0.02) | |
Research and Development Expense of Revenue |
70.66% | 346.16% | 229.72% | 62.12% | |
Selling, General and Administrative Expense of Revenue |
20.25% | 97.47% | 62.64% | 17.20% | |
Share Based Compensation of Revenue |
21.21% | 99.91% | 63.04% | 17.67% | |
Operating CF/Net income |
1.43 | (0.44) | 1.02 | 1.58 | |
Depreciation/Fixed assets |
(1.45) | (1.13) | (0.81) | (0.57) | |
Capex/Depreciation |
0.29 | 0.37 | 0.41 | 0.31 | |
Revenue per Share |
3.28 | 0.72 | 1.14 | 4.28 | |
Operating CF per Share |
1.03 | 0.91 | (1.79) | 1.99 | |
Capex per Share |
(0.03) | (0.02) | (0.02) | (0.01) | |
Capex to Sales |
0.01 | 0.03 | 0.02 | 0.00 |
Columns are period end dates